Bio-Thera Solutions, Ltd. (Shanghai Stock Exchange: 688177) has received marketing approval from China’s National Medical Products Administration for BAT2506, making it the first golimumab biosimilar authorised in the Chinese market. Announced internationally on 6 November 2026, the approval permits the product, marketed as ASHULI, to be used for rheumatoid arthritis and ankylosing spondylitis, expanding the company’s commercial opportunities in autoimmune diseases.
The regulatory decision represents the third major regional authorisation milestone for Bio-Thera’s golimumab programme in 2026. The same underlying biosimilar development programme received European Union marketing authorisation in February under the Gotenfia brand, followed by United States Food and Drug Administration approval in May for Immgolis and Immgolis Intri.
For Bio-Thera, the Chinese approval is strategically important because it establishes a locally authorised biosimilar alternative to Johnson & Johnson’s established golimumab franchise. However, the development’s financial significance will depend on launch readiness, pricing, reimbursement access, physician acceptance and competition within China’s broader biological treatment market.
The milestone also provides a clearer view of Bio-Thera’s international business model. Rather than relying exclusively on domestic sales, the Guangzhou-based biopharmaceutical company has developed BAT2506 through a network of licensing and commercialisation partners spanning multiple regions, creating opportunities for revenue generation across different regulatory and healthcare systems.
What exactly has China’s NMPA approved for Bio-Thera’s BAT2506 golimumab biosimilar?
The National Medical Products Administration approved BAT2506 as a therapeutic biological product under China’s biosimilar regulatory framework. The product’s Chinese commercial name is ASHULI, and its registration covers rheumatoid arthritis and ankylosing spondylitis. The approved presentation includes a 50 mg/0.5 mL prefilled syringe intended for subcutaneous administration.
Bio-Thera’s regulatory filing identifies the product as a golimumab injection, with Chinese marketing authorisation number S20260080. The company’s exchange announcement dated 6 November confirms receipt of the drug registration certificate, establishing the approval as a completed regulatory decision rather than an application acceptance or pending review.
The product is a biosimilar to golimumab, the active substance in Johnson & Johnson’s Simponi. Golimumab is a human monoclonal antibody targeting tumour necrosis factor alpha, an inflammatory signalling protein involved in several immune-mediated diseases. By inhibiting this pathway, golimumab can reduce inflammatory activity in appropriately selected patients.
Biosimilar medicines are developed to demonstrate high similarity to an authorised reference biological product, with no clinically meaningful differences in the relevant aspects of safety, efficacy and quality. Unlike conventional generic medicines, biosimilars generally require extensive analytical characterisation of complex biological molecules, together with additional evidence appropriate to the product and regulatory pathway.
BAT2506’s approval should therefore be understood as a biosimilar marketing authorisation, not approval of a new mechanism of action. The commercial proposition centres on providing an additional version of an established biological medicine while potentially improving competition and affordability.
The Chinese indication is also narrower than the complete international range of uses associated with golimumab. Although reference golimumab products have been authorised for several immune-mediated conditions in different countries, BAT2506’s Chinese approval is specifically for rheumatoid arthritis and ankylosing spondylitis. It should not be interpreted as authorisation for ulcerative colitis, psoriatic arthritis or other indications that may be covered under separate regional labels.
Why does China’s first golimumab biosimilar approval matter for rheumatoid arthritis treatment?
Rheumatoid arthritis is a chronic inflammatory autoimmune disease that can cause progressive joint damage, pain and functional impairment. Biological disease-modifying antirheumatic drugs, including tumour necrosis factor inhibitors, have become established treatment options for appropriate patients whose disease remains inadequately controlled with conventional therapies.
Golimumab belongs to a mature class of biological medicines that includes several other tumour necrosis factor inhibitors. Its clinical role is therefore supported by an established therapeutic mechanism, although treatment selection depends on disease characteristics, previous treatment response, contraindications and applicable prescribing guidance.
The arrival of a biosimilar can influence competition by introducing another supplier of an existing biological therapy. In markets where biosimilars achieve sufficient adoption, they may place downward pressure on treatment costs and support broader patient access. However, regulatory approval does not itself establish that a particular biosimilar will be priced below the reference product or secure substantial market share.
For China, affordability and access are especially relevant because the treatment of chronic autoimmune diseases may involve prolonged medication use and regular monitoring. Biological treatment costs can influence formulary decisions, reimbursement policy and the availability of therapy across different healthcare settings.
ASHULI’s potential impact will depend on the actual commercial terms established after approval. These include its launch price, reimbursement status, hospital inclusion and availability through relevant distribution channels. Without those details, the announcement supports a competitive access opportunity rather than a quantifiable reduction in treatment costs.
The distinction is commercially important for Bio-Thera. A large population with autoimmune disease does not automatically translate into a large addressable market for a single biosimilar. The number of eligible patients, treatment guidelines, competition from other biological medicines and prescribing practices will all influence the realistically accessible market.
The company will also need to demonstrate that manufacturing capacity and distribution arrangements can support reliable supply. For long-term immune-mediated disease treatment, interruptions in medicine availability can complicate clinical management and undermine confidence among prescribers and procurement organisations.
How could BAT2506 compete against Johnson & Johnson’s established Simponi franchise?
Johnson & Johnson’s Simponi franchise represents the reference-product market against which BAT2506 will compete. The original golimumab product received Chinese marketing approval in 2017, establishing a substantial period of commercial and clinical experience before the arrival of the first domestic biosimilar.
Bio-Thera cited Johnson & Johnson’s 2025 annual reporting, which recorded approximately US$2.668 billion in worldwide Simponi net sales. That figure demonstrates the international commercial scale of the established molecule, but it should not be treated as the revenue opportunity available to BAT2506 in China.
The global sales figure includes activity across markets with different approved indications, formulations, reimbursement systems and competitive conditions. It therefore provides context for the size of the reference franchise rather than a direct estimate of future biosimilar revenue.
In China, BAT2506’s initial commercial position will be shaped by competition not only with Simponi but also with other established therapies for rheumatoid arthritis and ankylosing spondylitis. These include different tumour necrosis factor inhibitors and medicines targeting other inflammatory pathways. Physicians may select treatment based on disease severity, previous response, clinical guidance and patient-specific considerations.
Biosimilar market share can also depend on whether healthcare institutions encourage prescribing of lower-cost alternatives. Hospital procurement arrangements, national and regional reimbursement mechanisms, and any applicable volume-based purchasing policies can influence product access. The specific treatment of ASHULI within these systems will matter more to commercial performance than its first-to-market designation alone.
Bio-Thera may benefit from being the first approved golimumab biosimilar in China because it can establish commercial relationships before additional biosimilar competitors enter the market. However, first approval does not guarantee market leadership, and competitors offering other biological treatments already have established commercial positions.
The company will need to balance pricing competitiveness with sustainable manufacturing economics. Aggressive discounting may help secure market access, but the financial value of additional volume depends on production costs, distribution expenses and the commercial arrangements supporting the product.
What does BAT2506’s US and European regulatory record reveal about its global development?
BAT2506’s Chinese approval follows a rapid sequence of international regulatory milestones during 2026. In February, the European Commission granted marketing authorisation for Gotenfia, with STADA Arzneimittel AG identified as the marketing authorisation holder. The authorisation followed the European Medicines Agency’s regulatory assessment of the biosimilar.
Gotenfia’s European indications cover several immune-mediated conditions, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis and certain paediatric inflammatory diseases. The permitted populations and treatment conditions are defined in the European prescribing information. These indications should not be transferred automatically to BAT2506’s Chinese label.
In May 2026, the United States FDA approved Immgolis and Immgolis Intri, the first biosimilars to Johnson & Johnson’s Simponi and Simponi Aria, respectively. Both products received interchangeable biosimilar status under the relevant US regulatory framework, which has distinct requirements and implications from an ordinary biosimilar approval.
Immgolis is approved in the United States for moderately to severely active rheumatoid arthritis in adults in combination with methotrexate, and moderately to severely active ulcerative colitis in adults. Immgolis Intri is approved for moderately to severely active rheumatoid arthritis in adults in combination with methotrexate. The two products have different routes of administration, with Immgolis administered subcutaneously and Immgolis Intri formulated for intravenous infusion.
The FDA stated that its approval was supported by extensive analytical comparisons and pharmacokinetic evidence demonstrating biosimilarity to the respective reference products. The assessment included evaluations of structural and functional characteristics, drug exposure and immunogenicity.
These findings establish an important regulatory foundation for Bio-Thera’s international programme. However, the US interchangeable designation is specific to the FDA’s approval and does not automatically establish equivalent substitution status under Chinese or European rules.
The sequence of authorisations also demonstrates that a single biosimilar development platform can support several region-specific regulatory submissions. Each jurisdiction nevertheless determines the authorised indications, product presentations and prescribing requirements through its own review process.
For Bio-Thera, the challenge now shifts from securing regulatory decisions to converting those authorisations into product availability and commercially sustainable sales.
How will Bio-Thera’s licensing partnerships influence BAT2506’s international revenue potential?
Bio-Thera has developed an extensive commercial partnership network for BAT2506, with licensing arrangements covering 118 countries and territories. The company has identified agreements involving Intas Pharmaceuticals, STADA Arzneimittel, SteinCares, Pharmapark and Dr. Reddy’s Laboratories across different regional markets.
Intas Pharmaceuticals is associated with rights covering the United States, Canada and India, with its Accord BioPharma business responsible for US commercialisation. STADA’s agreement covers the European Union, the United Kingdom, Switzerland and additional territories in Europe, the Middle East and North Africa.
Other regional partnerships include SteinCares in Latin America, Pharmapark in Russia and selected Commonwealth of Independent States markets, and Dr. Reddy’s Laboratories across several Southeast Asian countries. These arrangements provide Bio-Thera with a geographically diversified commercial structure without requiring the company to establish a fully independent sales organisation in every market.
However, the financial contribution from these agreements depends on their contractual terms. Licensing structures may involve upfront payments, regulatory milestones, commercial milestones, manufacturing supply revenue or royalties, but the November approval announcement does not provide a new breakdown of the economics attributable to BAT2506’s Chinese authorisation.
It would therefore be premature to translate the number of licensed territories into expected revenue. Some markets have already granted authorisation, while others remain subject to regulatory review or subsequent commercial implementation.
Brazil represents one example of an additional market where Bio-Thera has pursued regulatory approval. Its Chinese exchange filing confirms that BAT2506 has been submitted to Brazil’s health regulator, with the application under review. A submitted application does not establish that the product has been authorised or commercially launched in that country.
The global licensing model also introduces supply-chain and operational responsibilities. Depending on the terms of individual agreements, Bio-Thera may need to coordinate manufacturing, quality assurance, product release, distribution and regulatory maintenance across multiple jurisdictions.
Reliable manufacturing performance will be particularly important because biosimilar regulators require consistency in critical quality attributes. Changes in production processes must be appropriately controlled, and commercial supply must remain compliant with applicable good manufacturing practice requirements.
What safety considerations remain important for BAT2506 as a TNF inhibitor biosimilar?
Although BAT2506 is a biosimilar to an established medicine, its use involves safety considerations associated with the golimumab molecule and the broader tumour necrosis factor inhibitor class. These medicines modify immune responses and can increase susceptibility to serious infections in certain patients.
US prescribing information for the related Immgolis products includes boxed warnings concerning serious infections and malignancies. Reported risks associated with golimumab products include tuberculosis, invasive fungal infections and other serious opportunistic infections. The medicines also require appropriate screening and clinical monitoring under their authorised prescribing information.
These warnings do not mean BAT2506 has demonstrated a distinct safety disadvantage compared with reference golimumab. The purpose of biosimilar development is to establish high similarity and the absence of clinically meaningful differences within the regulatory evidence framework.
Nevertheless, approval should not be interpreted as an absence of safety risks. Clinicians must consider the established precautions associated with the biological treatment, together with the specific authorised Chinese product information.
Post-marketing pharmacovigilance will remain important as the medicine enters routine use. Monitoring can help identify uncommon adverse events, support continued evaluation of immunogenicity and provide additional information about real-world treatment experience.
The clinical evidence supporting biosimilarity should also be distinguished from claims of therapeutic superiority. BAT2506 is not being introduced as a medicine that has demonstrated better disease control than Simponi. Its principal proposition is to provide another authorised version of golimumab, potentially increasing treatment options and competition.
What do Bio-Thera’s latest financial results indicate about commercial execution and funding needs?
Bio-Thera’s regulatory progress comes against a financial backdrop of growing revenue and substantial research expenditure. In its financial results for the first nine months of 2026, the company reported operating revenue of approximately CNY797.6 million, representing an increase of 16.68% from the corresponding period in 2025.
The company also reported a net loss attributable to shareholders of approximately CNY332.9 million for the nine-month period. Research and development expenditure reached approximately CNY688.3 million, compared with CNY556.7 million in the previous year’s corresponding period.
These figures illustrate the financial demands associated with developing an international portfolio of innovative medicines and biosimilars. Revenue growth provides evidence of an expanding commercial business, but research expenditure and operating costs continue to place pressure on profitability.
The BAT2506 approval may create an additional route towards future revenue diversification. However, the announcement does not disclose a confirmed Chinese launch date, product price, contracted sales volume or expected revenue contribution. The immediate financial effect cannot therefore be quantified from the regulatory decision alone.
Commercial execution will depend on the company’s ability to supply the market while preserving a viable margin structure. Manufacturing investment, quality assurance, sales infrastructure and market access activities may require expenditure before meaningful product revenue is generated.
Bio-Thera’s wider portfolio also creates competing demands for capital. The company is developing innovative oncology assets alongside its biosimilar programmes, with several drug candidates progressing through clinical evaluation. Balancing those investments against the requirements of an expanding international commercial business will remain an important financial consideration.
How did Bio-Thera shares perform around the BAT2506 approval announcement?
Bio-Thera’s Shanghai-listed shares closed at approximately CNY17.81 on 6 November 2026, compared with CNY17.82 in the previous session, representing a decline of around 0.06%. The stock had recovered from its 30 October closing level of CNY16.36, gaining approximately 8.9% over the five subsequent trading sessions.
The available market data placed the shares within a 52-week trading range of approximately CNY15.57 to CNY27.10. The November closing price was therefore substantially below the upper end of the annual range, despite the recent recovery.
The performance suggests that investors have been reassessing the company during a period of regulatory progress, but the stock movements should not be attributed solely to the BAT2506 approval. Bio-Thera has other commercial and clinical programmes, and wider market conditions can also influence its valuation.
The modest movement on 6 November is particularly relevant because a regulatory milestone does not necessarily translate into an immediate and sustained share-price increase. The company’s financial results, expected development expenditure and ability to generate cash from approved products remain important considerations.
From an investor perspective, BAT2506’s approval is best understood as regulatory de-risking rather than evidence of near-term earnings expansion. The uncertainty associated with obtaining Chinese authorisation has been reduced, but commercial performance remains dependent on pricing, reimbursement, product supply and market penetration.
The next financial disclosures will be useful in determining whether Bio-Thera’s growing number of approved biosimilars is translating into stronger operating leverage. Investors will also need to distinguish revenue earned directly from product sales from revenue arising through licensing, manufacturing services and other commercial arrangements.
What will determine whether China’s first golimumab biosimilar becomes a commercial success?
The most immediate milestone for Bio-Thera is the practical availability of ASHULI in the Chinese market. Regulatory authorisation permits commercialisation within the approved indication, but it does not establish that the medicine has reached hospitals or pharmacies at scale. Product distribution, launch sequencing and manufacturing readiness will therefore shape the initial commercial period.
Pricing and reimbursement are likely to be central determinants of market adoption. If ASHULI offers a competitive acquisition cost while meeting relevant quality and supply requirements, it could become attractive to institutions seeking additional golimumab treatment options. However, the magnitude of any potential savings will depend on actual transaction prices and applicable reimbursement arrangements.
Physician acceptance will be another consideration. Biosimilars benefit from extensive regulatory assessment, but adoption patterns may vary according to clinical familiarity, institutional policies and patient circumstances. Clear communication of the approved indications and biosimilar evidence can support informed prescribing without implying superiority over the reference product.
The company’s international partnerships provide additional opportunities to spread commercial and operational risk across multiple markets. Nevertheless, those arrangements will create meaningful financial value only as approved products reach patients and generate revenue under the applicable agreements.
The FDA and European authorisations achieved earlier in 2026 have already established BAT2506 as an internationally approved biosimilar programme. China’s approval extends that regulatory footprint to the company’s home market, where the new product will compete within an established and increasingly diversified autoimmune treatment sector.
For Bio-Thera Solutions, the November decision represents a substantial regulatory achievement and another step towards monetising its biosimilar development capabilities. The next test will be whether the company can convert first-to-market status into sustainable Chinese sales while supporting international supply commitments and controlling research expenditure. BAT2506’s commercial performance, rather than the number of regulatory approvals alone, will determine the financial value of the milestone.
